Clinical trial

Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.

Name

CHUBX 2023/79

Description

Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.

Trial arms

Trial start

2024-05-01

Estimated PCD

2025-07-01

Trial end

2026-04-01

Status

Not yet recruiting

Treatment

Relapsed glioblastoma

Paired tumor samples diagnosis/relapse

Arms:

Patients operated for primary and recurrent glioblastoma

Size

Primary endpoint

Evaluation of metabolic changes involved in glioblastoma relapse

Up to 2 years after the start of the study

Eligibility criteria

Inclusion Criteria: * age \> 18 years * surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux Exclusion Criteria: * systemic therapy received for non-glioblastoma tumor

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}

Updated at

2024-05-28

1 organization

1 product

2 indications

Organization

University Hospital Bordeaux

Product

Relapsed Glioblastoma

Indication

Relapsed Cancer

Indication

Glioblastoma IDH Wildtype